CNS Amyloid-β, Soluble APP-α and-β Kinetics during BACE Inhibition by Dobrowolska, Justyna A et al.




CNS Amyloid-β, Soluble APP-α and-β Kinetics
during BACE Inhibition
Justyna A. Dobrowolska
Washington University School of Medicine in St. Louis
Bruce W. Patterson
Washington University School of Medicine in St. Louis
Robert Chott
Washington University School of Medicine in St. Louis
Vitality Ovod
Washington University School of Medicine in St. Louis
Yuriy Pyatkivskyy
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Dobrowolska, Justyna A.; Patterson, Bruce W.; Chott, Robert; Ovod, Vitality; Pyatkivskyy, Yuriy; Wildsmith, Kristin R.; Kasten, Tom;
Yarasheski, Kevin E.; Bateman, Randall J.; and et al, ,"CNS Amyloid-β, Soluble APP-α and-β Kinetics during BACE Inhibition." The
Journal of Neuroscience.34,24. 8336-8346. (2014).
http://digitalcommons.wustl.edu/open_access_pubs/2988
Authors
Justyna A. Dobrowolska, Bruce W. Patterson, Robert Chott, Vitality Ovod, Yuriy Pyatkivskyy, Kristin R.
Wildsmith, Tom Kasten, Kevin E. Yarasheski, Randall J. Bateman, and et al
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2988
Cellular/Molecular
CNS Amyloid-, Soluble APP- and - Kinetics during
BACE Inhibition
X Justyna A. Dobrowolska,1Maria S. Michener,5 GuoxinWu,3 BruceW. Patterson,2 Robert Chott,2 Vitaliy Ovod,1
Yuriy Pyatkivskyy,1 Kristin R. Wildsmith,1 TomKasten,1 Parker Mathers,5Mandy Dancho,5 Christina Lennox,5
Brad E. Smith,5David Gilberto,5Debra McLoughlin,8Daniel J. Holder,7 AndrewW. Stamford,6
Kevin E. Yarasheski,2Matthew E. Kennedy,4Mary J. Savage,3 and Randall J. Bateman1
1Departments of Neurology and 2Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 and 3Molecular Biomarkers,
4Neuroscience, 5Safety and Laboratory Animal Resources, 6Medicinal Chemistry, 7Early Development Statistics, and 8Preclinical Drug Metabolism, Merck
Research Laboratories, West Point, Pennsylvania 19486 and Kenilworth, New Jersey 07033
BACE, a-secretase, is an attractive potential disease-modifying therapeutic strategy forAlzheimer’s disease (AD) as it results directly in
the decrease of amyloid precursor protein (APP) processing through the -secretase pathway and a lowering of CNS amyloid- (A)
levels. The interaction of the -secretase and -secretase pathway-mediated processing of APP in the rhesus monkey (nonhuman
primate; NHP) CNS is not understood.We hypothesized that CNS inhibition of BACEwould result in decreased newly generated A and
soluble APP (sAPP), with increased newly generated sAPP.
A stable isotope labeling kinetics experiment in NHPswas performedwith a 13C6-leucine infusion protocol to evaluate effects of BACE
inhibition onCNSAPPprocessing bymeasuring the kinetics of sAPP, sAPP, andA in CSF. EachNHP received a low,medium, or high
doseofMBI-5 (BACE inhibitor) or vehicle in a four-way crossoverdesign.CSF sAPP, sAPP, andAweremeasuredbyELISAandnewly
incorporated label following immunoprecipitation and liquid chromatography-mass spectrometry. Concentrations, kinetics, and
amount of newly generated APP fragments were calculated.
sAPP and sAPP kinetics were similar, but both significantly slower than A. BACE inhibition resulted in decreased labeled sAPP
and A in CSF, without observable changes in labeled CSF sAPP. ELISA concentrations of sAPP and A both decreased and sAPP
increased. sAPP increased by ELISA, with no difference by labeled sAPP kinetics indicating increases in product may be due to APP
shunting from the -secretase to the -secretase pathway. These results provide a quantitative understanding of pharmacodynamic
effects of BACE inhibition on NHP CNS, which can inform about target development.
Key words: amyloid beta; amyloid precursor protein; BACE inhibitor; sAPP; sAPP; SILK
Introduction
Amyloid precursor protein (APP) is a ubiquitous transmembrane
protein involved in cell signaling, development, andgene regulation.
Compared with peripheral, non-CNS tissues, CNS APP processing
demonstrates increased -secretase (BACE) activity (Irizarry et al.,
2001; Fukumoto et al., 2002) and different responses to -secretase
modulation (Cook et al., 2010). The differences between APP pro-
cessing in the CNS and peripheral compartments are not fully un-
derstood (Ortega et al., 2013); further understanding of APP
processingmaybe important to inform thedesign anddevelopment
of Alzheimer’s disease (AD) therapeutics.
APP is first cleaved by either BACE or -secretase enzyme
generating extracellular soluble APP- (sAPP) or sAPP, re-
spectively (Fig. 1). Following BACE cleavage, the APPC-terminal
fragment C99 can be cleaved by -secretase producing extra-
cellular amyloid- (A) and the remaining APP intracellular
C-terminal domain. Recent reports (Cook et al., 2010; Portelius
et al., 2011) indicate there is an alternate pathway of a tandem
-secretase and BACE cleavage of APP, which results in APP
metabolites such as A1–15/1–16. The relationship of physiolog-
ical -secretase to BACE processing in the CNS is not fully un-
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derstood, although some insights from inhibition studies of these
enzymes suggest that APP can be shunted to other pathways
(Mattsson et al., 2012).
BACE inhibition has been proposed to decrease the amount of
APP processed into A, and shunt APP to the -secretase path-
way. BACE1 appears to be the predominant BACE in the CNS
and is located mainly in the membranes of cellular compart-
ments. BACE1may be increased2-fold in brains (Fukumoto et
al., 2002; Li et al., 2004; Yang et al., 2003) or CSF of AD patients
(Holsinger et al., 2006; Verheijen et al., 2006; Zetterberg et al.,
2008), although recent reports suggest little change from healthy
controls (Wu et al., 2011; Rose´n et al., 2012; Savage et al., 2013).
Brain penetrant BACE1 inhibitors capable of loweringCNSA in
rodent and nonhuman primate (NHP) models (Sankaranaray-
anan et al., 2009; Malamas et al., 2010; Takahashi et al., 2010;
Truong et al., 2010; Cumming et al., 2012; Mandal et al., 2012;
Stamford et al., 2012) have been identified and multiple BACE
inhibitors have advanced into early stages of human clinical trials
(May et al., 2011; Egan et al., 2012, Forman et al., 2013; Bernier et
al., 2013).
We sought to determine the kinetic behavior of APP metabo-
lites and the relationship between the -secretase and BACE
pathways during BACE inhibition in rhesus macaques, an NHP
model that has 91%homology of APPwith humanAPP.We used
stable isotope labeling kinetics (SILK) in combination with a
novel high-affinity, selective, and centrally active BACE inhibitor
to monitor the production and turnover of APP metabolites. By
distinguishing the newly generated metabolites in the CSF from
those that previously existed, SILK has provided a more sensitive
determination of minute changes in APPmetabolites in sporadic
and autosomal dominant AD (Mawuenyega et al., 2010; Potter et
al., 2013). In the context of -secretase inhibition, SILK demon-
strated low-dose -secretase inhibition effects on A production
(Bateman et al., 2009).
Materials andMethods
Cisterna magna ported conscious NHP model.
Animal use procedures in this study were re-
viewed and approved by the Institutional Ani-
mal Care and Use Committee at Merck
Research Laboratories. They conform to the
Guide for the Care and Use of Laboratory An-
imals (Institute of Laboratory Animal Re-
sources, National Research Council, 1996).
The cisterna magna ported (CMP) stable cath-
eterization procedures and CSF flow and col-
lection, as well as the vascular access port
infusion protocol, were as described previously
(Gilberto et al., 2003; Cook et al., 2010).
13C6-leucine infusion protocol and sample col-
lection. At 48 h before administration of com-
pound or vehicle, monkeys were restricted to a
protein-free diet consisting of fruits and vege-
tables. Protein was reintroduced after the 12 h
time point of the study (13 h post dosing of the
BACE inhibitor). 13C6-leucine infusion proce-
dures were described previously (Cook et al.,
2010). Briefly, a 4 mg/kg [U-13C6] leucine
priming dose was administered intravenously
for 10 min, followed by a steady infusion of 4
mg/kg/h for 12 h. Baseline CSF and blood sam-
ples were collected at22,20, and1 h be-
fore primed leucine administration. CSF and
blood sampleswere collected at 2, 4, 6, 8, 12, 15,
18, 21, 24, 27, 30, 48, 54, 57, 72, and 144 h after
the start of tracer leucine administration. At
each time point, a total of 1.5 ml CSF was col-
lected into low-binding polypropylene tubes (Axygen Scientific). The
bloodwas collected into K2 EDTAVacutainer tubes (BectonDickinson),
spun, and 800 l of plasma was collected. CSF and plasma samples were
then separated into aliquots of lesser volume (into Axygen or standard
polypropylene tubes) and placed immediately on dry ice, then stored in a
70°C freezer until analysis.
BACE inhibitor study protocol. TheMerck BACE inhibitor, MBI-5 (see
Table 1 for pharmacological profile), was used in a four-way crossover
randomized design administering one of three doses. Vehicle (0.4%
methylcellulose), or 10, 30, and 125 mg/kg MBI-5 was administered
orally to conscious CMPNHP (n 5male rhesus monkeys, 10–13 years
old, 8–15 kg) 1 h before initiating the tracer leucine administration. CSF
and plasma samples were collected as described above to assess the phar-
macokinetics (PK) and pharmacodynamics (PD) of this compound by
quantifying MBI-5 concentrations (in plasma and CSF); absolute CSF
concentrations of sAPP, sAPP, A1–40, and A1–42 (as measured by
ELISA); or 13C6-leucine/
12C6-leucine-labeled CSF sAPP, sAPP, and
total A; and free 13C6-leucine/
12C6-leucine enrichment in plasma. Ve-
hicle/BACE inhibitor administration and sample collection took place at
Merck Research Laboratories. Subsequent PK analyses and CSF ELISA
measurements also took place at Merck, whereas CSF and plasma were
shipped on dry ice to Washington University for SILK analyses: all serial
immunoprecipitation (IP)/mass spectrometry (MS) analyses, as well as
analyses of total leucine enrichment. Cell culture to generate APP stan-
dards for SILK also took place at Washington University.
Cell culture to generate 13C6-leucine/
12C6-leucine APP fragment stan-
dards. Human H4 neuroglioma cells stably transfected with human
APP751 (H4-APPwt; courtesy of T. E. Golde, University of Florida,
Gainesville) were grown in DMEM (Sigma-Aldrich) for two passages.
Leucine-free DMEM (Sigma-Aldrich) was supplemented with a mixture
of 13C6-leucine
12C6-leucine to generate final media solutions with a
range of 0%, 1.25%, 2.5%, 5%, 10%, or 20% 13C6-leucine. Total leucine
concentrations across the mixtures were identical to standard DMEM
(105mg/L).DMEMsolutionswere supplementedwith 1:50B-27 and 1%
each of penicillin-streptomycin and Zeocin. At the third passage, cells
were pooled and split evenly at 80% confluency in T-75 flasks. The
Figure 1. APP and secretase cleavage sites. APP may be cleaved by either - or -secretase, and subsequently cleaved by
-secretase. A concerted-/-secretase cleavage releases A. Indicated on this schematic are the regions of APPwhere peptides
for the SILK study are used to determine labeling of APPmetabolites. The sAPP and sAPP peptide (KYLETPGDENEHAHFQ) is in
the mid-domain of APP. The A peptide (KLVFFAEDVGSN) is located in the middle of the A sequence. We hypothesize that APP
that remains uncleaved by-secretase due to the presence of a BACE inhibitor will be available for cleavage by-secretase.
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H4-APPwt cells were reconstituted in one of the six prepared media so-
lutions and cultured for 24 h to allow for sufficient incorporation of label
into proteins. Following this incubation with labeled DMEM, the media
solutions were collected and apportioned into Axygen tubes in 1 ml
aliquots and immediately frozen and stored at80°C until ready to use.
A, sAPP, and sAPP ELISA protocols. The assays for CSF A1–40,
A1–42, sAPP, and sAPP measurement were described previously
(Sankaranarayanan et al., 2009; Wu et al., 2011) with somemodification
in dilution factor. Briefly, CSF was diluted with 3% BSA/PBS at 1:3 for
A1–42, 1:10 for A1–40, and 1:80 for both sAPP and sAPP and used at
100l per ELISAwell for each analytemeasurement. The concentrationwas
calculated based on each standard curve. The absolute concentrations of
total A reported herein are derived by adding the absolute concentrations
measured by the two individual A ELISAs: A1–40 and A1–42.
IP and digestion of sAPP. IP of sAPP fromCSF was performed using
a rabbit monoclonal antibody that can specifically recognize the KM-
neo-epitope of sAPP created following the cleavage of APP by BACE.
The generation and specificity characterization of the prepared anti-
sAPP neo-epitope antibody Mrk-61 was previously described (Wu et
al., 2011;Wu et al., 2012).Mrk-61 binds exclusively to sAPP, and not to
sAPP, in both Western blot and direct immunoassay experiments that
use coated recombinant protein. The purified rabbit monoclonal anti-
Mrk-61 antibody was conjugated with CNBr-activated Sepharose 4B
beads (GE Healthcare) according to the manufacturer’s protocol. The
activity of the Sepharose 4B-conjugated Mrk-61 antibody was evaluated
for IP efficiency with normal NHP CSF following overnight bead incu-
bation and the sAPP level in CSF after IP was measured with a sensitive
sAPP ELISA (Wu et al., 2011). The characterizedMrk-61-Sepharose 4B
beadswere then reconstituted into a 50% slurry of 0.02% sodiumazide in
PBS and stored at 4°C.
From each time point, 500l of CSF, in parallel with a set ofH4-APPwt
media isotopic enrichment standards (0, 1.25, 2.5, 5, 10, and 20% 13C6-
leucine), was diluted 1:1 with 500 l PBS. Protease inhibitors (40 g/ml
aprotinin and 20 g/ml leupeptin; Calbiochem/EMD Millipore) were
added to each sample at a volume of 10l, followed by the addition of 50
l of Mrk-61 beads.
Samples were rotated for22 h at 4°C, then centrifuged (16,837 g)
with 925 l of resulting supernatants collected into new Axygen tubes
and stored at 4°C for1.5 h until ready for the sAPP/A immunopre-
cipitation protocol. The Mrk-61 bead pellets were washed three times
with 25 mM ammonium bicarbonate (AmBic), with centrifugation be-
tween washes. The supernatants from the bead washes were aspirated
after the final rinse and 100l of neat formic acidwas immediately added
to each sample to elute the sAPP from the antibody-bead complex.
Samples were left for 10 min at 25°C and centrifuged. The formic acid
supernatants were transferred to a new Axygen tube and evaporated in a
rotary evaporator at 37°C for 30 min. The dried samples were reconsti-
tuted with 25 mM AmBic, and 5 ng sequencing-grade metalloendopepti-
dase (Lys-N; Seikagaku/Associates of Cape Cod) in 25 mM AmBic was
added. Extracts were digested for 20 h on a shaker at 37°C and trans-
ferred into autosampler vials.
IP and digestion of sAPP and A. Before study onset, a mouse mono-
clonal antibody W0–2 (EMD Millipore; directed against A1–10) and a
mouse monoclonal antibody HJ5.1 (Washington University, St. Louis,
MO; directed against A13–28)were covalently bound toCNBr Sepharose
4B beads according to the manufacturer’s instructions, then stored in a
50% slurry of 0.02% PBS azide at 4°C before use. The sAPP/A IP
protocol was optimized for maximum sAPP/A signal from the liquid
chromatography-mass spectrometer (LC-MS) system. The above-
mentioned CSF samples and H4-APPwt media APP standard superna-
tants were taken from 4°C and put on ice. To each sample 45 l W0–2
antibody slurry and 60 l HJ5.1 antibody slurry were added. Samples
were rotated, rinsed, eluted, evaporated, reconstituted, and digested us-
ing the same methods applied to the Mrk-61 bead eluates.
Quantitation of peptides by LC-MS.Mid-domain APP peptides specific
to sAPP and sAPP (KYL(L*)ETPGDENEHAHFQ), and a mid-
domain A peptide (KL(L*)VFFAEDVGSN; Fig. 1) were analyzed on a
Thermo-Finnigan LTQ (Thermo Fisher Scientific) equipped with nano-
flow electrospray ionization (nano-ESI; NewObjective) source. The pep-
tides were separated by reverse phase HPLC using a 2D-LC nanoflow
pump (Eksigent) operating in 1D mode at a flow rate of 200 nl/min.
Sample (5 l) was injected onto a PicoFrit column (New Objective)
packed to 12 cm with 5 m Magic C18aq packing material (Michrom
Bioresources).Mobile Phase A contained 0.1% formic acid (FA) in water
and Mobile Phase B was 0.1% FA in acetonitrile.
Free leucine quantitation by gas-chromatography-mass spectrometry.
Plasma 13C6-leucine/
12C6-leucine enrichment was determined using gas
capillary gas chromatography-mass spectrometry (GC-MS; Agilent
6890N gas chromatograph and Agilent 5973Nmass selective detector) in
negative chemical ionizationmode as described previously (Yarasheski et
al., 1992; Bateman et al., 2007; Cook et al., 2010), and 13C6-leucine en-
richment was quantified as a relative measure, tracer to tracee ratio
( 13C6-leucine/
12C6-leucine; Wolfe et al., 2005).
Calculation of labeled APP metabolite ratio. The percentage of labeled
metabolite measured using the SILK method was determined by tak-
ing the ratio of b- and y-product ion intensities from the unlabeled
metabolite peptide and the labeled peptide. For A, the peptide quan-
tified was KL(L*)VFFAEDVGSN. For sAPP and sAPP, the peptide
was KYL(L*)ETPGDENEHAHFQ. Mole fraction label (MFL) was cal-
culated as MFL L/(LU ), where L andU are the signal intensities for
13C6-leucine (labeled) peptides and
12C6-leucine (unlabeled) peptides,
respectively.
Calculations of fractional synthesis rate and monoexponential slope frac-
tional clearance rate. The fractional synthesis rate (FSR) and monoexpo-
nential slope fractional clearance rate (FCR) were quantified for each
metabolite as previously reported (Cook et al., 2010). Briefly, FSR for
each CSF APP metabolite was calculated as the slope of the labeled me-
tabolite during 2–8 h, divided by the average plasma 13C6-leucine en-
richment over that time course. The monoexponential slope FCR was
computed using the natural logarithm of each labeled metabolite during
the clearance phase of the labeled proteins, notably 18–30 h.
Calculation of newly generated APP metabolites. The concentration of
newly generated APPmetabolites at each time point was calculated as the
product of the absolute concentration of a metabolite (determined by
ELISA) and the fraction of themetabolite derived from de novo synthesis,
i.e., the percentage of metabolite labeled (13C6-leucine-peptide/
12C6-
leucine-peptide ion intensities, established by LC-MS) after normaliza-
tion to the plasma 13C6-leucine/
12C6-leucine enrichment, established by
GC-MS (Bateman et al., 2009).
Area under the curve and statistical analyses. For each APP analyte and
drug exposure, area under the curve (AUC) was calculated using the
trapezoid rule, from1 to 57 h (AUC57) for APP analytes and from 0 to
59 h (AUC59) for drug. These time durations were chosen due to the
majority of the drug effects and labeling occurring over this period. To
estimate the effect of each active treatment versus vehicle, a linear mixed
effects model with fixed effects for treatments and random effects for
monkeys was fit to the log (base 2) of AUC57. Estimates of mean differ-
ences from vehicle were back-transformed from the log scale to yield
percentage differences. Estimation of the linear relationship between
each analyte and drug exposure was performed using a mixed effects
model like the one above, except with the treatment effects replaced by a
slope and intercept for exposure. Error bars reported in the figures rep-
Table 1. In vitro pharmacological profile of the BACE inhibitor, MBI-5
Ki , IC50 , nM, or ED50 mg/kg, p.o.
Soluble BACE1 10 1
SolubleBACE2 12 2
Cathepsin D 2700 600
Cathepsin E 26,600 11,000
Pepsin 70,000
Renin 9000
HEK293 APP swe/lon A40 IC50 72 5
HEK293 APP swe/lon A42 IC50 24 6
HEK293 APP swe/lon sAPP IC50 230
Rat plasma A1–40 0.4
Rat CSF A1–40 8
Rat cortex A1–40 23
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resent SD or SEM (clarified within figure legends). Mean-to-standard
deviation (MTSD) values (inverse of coefficient of variation) were calcu-
lated using eachmetabolite’s AUC57 mean and SD as calculated by SILK,
as well as by ELISA. Each metabolite’s MTSDs for SILK and ELISA were
compared to determine the relative sensitivity of the assays in this study.
All analyses and statistical tests were performed in GraphPad Prism ver-
sion 5.01 for Windows (GraphPad Software) and Microsoft Office Excel
2007. Student’s t test and repeated-measures analysis of variance
(ANOVA)were used to determinewhether therewere differences among
groups in all analyses. Baseline ELISA concentrations of APPmetabolites
were averaged for each monkey. Means were converted to log values and
Pearson correlations between each set of APP metabolites were
determined.
Results
Rhesus macaque APPmetabolite kinetics
sAPP and sAPP turnover was slower than A in the CSF. The
average kinetic curves of sAPP, sAPP, and A in the vehicle-
treated group were evaluated (Fig. 2A), comparing CSF parame-
ters including maximum MFL and time of maximum peak
labeling. Soluble APP achieved a maximum of 0.076  0.01
(SD) MFL, while sAPP exhibited a similar labeling maximum
[0.075 0.01 (SD)MFL; p 0.76; Fig. 2B]. Ahad a significantly
higher peak of MFL [0.094  0.01 (SD)] compared with both
sAPP and sAPP (*p  0.02 each; Fig. 2B). The extrapolated
maximum labeling time point for sAPP and sAPPwere similar
[sAPP: t 16.8 0.4 h (SD); sAPP: t 17.3 0.4 h (SD) *p
0.05], with the A labeling peak significantly earlier [t 14.2
0.5 h (SD) compared with sAPP, ***p 0.0005; compared with
sAPP, ***p 0.001; Fig. 2C].
Kinetic rates of the APPmetabolites were estimated using FSR
to estimate production rate and monoexponential slope FCR to
estimate clearance rate. CSF measures were used throughout as a
surrogate for brain rates. FSRs andmonoexponential slope FCRs
are only valid when measured in a steady-state system (Wolfe et
al., 2005), thus kinetic analyses of sAPP, sAPP, and A were
performed exclusively using data collected from the vehicle-
treatedmonkeys. Themean sAPP FSR [3.8 0.4%/h (SD)] was
18% faster than themean sAPP FSR [3.1 0.5%/h (SD), *p
0.01; Fig. 2D]. Themean A FSR was 7.3 0.9%/h (SD; Fig. 2D)
and was slightly lower than the previously reported NHPA FSR
(dashed red line) of 10.7 0.6%/h (SEM; Cook et al., 2010). The
mean A FSR was 58 and 48% faster than that of either sAPP
(***p 0.0002) or sAPP (***p 0.0006), respectively.
Mean FCRs for sAPP and sAPP were 7.8  0.7 (SD) and
8.3  1.4%/h (SD), respectively (Fig. 2E). Mean A FCR was
13.0  1.9%/h (SD; Fig. 2E) and was slightly faster than the
previously reported NHP A FCR (dashed red line) of 9.9 
0.5% /h (SEM; Cook et al., 2010), as well as approximately twice as
fast asmeanhumanAFCR(dashedblack line)previously reported
(Bateman et al., 2006). TheFCRsof all threemetaboliteswere signif-
icantly different (**p  0.002) as assessed by a one-way repeated-
measures ANOVA. A FCR was significantly faster than FCR of
either sAPP (*p  0.02) or sAPP (**p  0.005), 36 and 40%
Figure 2. Kinetics of APPmetabolites asmeasured from vehicle-treated NHP CSF (n 5).A, Averaged 13C6-leucine labeling curve profiles of sAPP, sAPP, and A.B, MaximumMFL for each
metabolite was determined. A reached a significantly highermaximum labeling as comparedwith sAPP (paired t test, *p 0.02) and sAPP (paired t test, *p 0.02). C, Extrapolated time of
maximum labeling was significantly different among metabolites, with A peaking at t 14.2 h, while sAPP and sAPP peaked at t 16.76 h and t 17.32 h, respectively (A vs. sAPP:
***p 0.0005; A vs. sAPP: ***p 0.001; sAPP vs. sAPP: *p 0.05).D,Mean FSRs indicating fraction-labeledAPPmetabolites’ appearance in the CSFwere significantly different fromone
another (repeated-measures ANOVA, ***p 0.0001). (A vs. sAPP: ***p 0.0002; A vs. sAPP: ***p 0.0006; sAPP vs. sAPP: *p 0.01) The red dashed line indicates the previously
reportedNHP FSRof A (10.7%/h; Cook et al., 2010).E,Meanmonoexponential slope FCRof A fraction-labeled loss fromCSFwas significantly higher than themonoexponential slope FCRs of both
sAPP (paired t test, **p 0.004) and sAPP (paired t test, *p 0.01). Therewas no statistically significant difference between sAPP and sAPPmonoexponential slope FCRs. The red dashed
line indicates previously reported NHP FCR of A (9.9%/h; Cook et al., 2010). The black dashed line indicates previously reported human FCR of A (8.3%/h; Bateman et al., 2006). Error bars
indicate SD.
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faster, respectively. The FCRs for sAPP and sAPPwere not signif-
icantly different from one another (p 0.6). For each metabolite,
the FSR is approximately half of the respective FCR. The discrep-
ancy between each metabolite’s FSR and FCR is currently be-
ing further evaluated by multicompartmental modeling.
Concentrations of MBI-5 were measured in the plasma (Fig.
3A–C) and CSF (Fig. 3D–F) of each subject to determine the
inhibitor’s PK at each of the three doses. Individual subjects’
AUC59 for MBI-5 in plasma (Fig. 3G) and in CSF (Fig. 3H) were
determined. The AUC59 was converted to a log scale and plotted
against dosage of MBI-5. Group-averaged AUC59 for plasma and
CSF are plotted against dose in Figure 3I. As expected, MBI-5
levels in both plasma andCSF increasedwith increasing dose, but
a linear effect was seen only in plasma. Individual plasma andCSF
AUC59 Cmax and Tmax for each subject at each dose are shown in
Tables 2, 3.
Biological variability of APP product concentrations
Some inherent physiological variability of APPmetabolites is ex-
pected. For each monkey, three baseline concentrations at t 
22,20, and1 h (before leucine infusion and treatment) of
sAPP, sAPP, and A (A40 A42) were measured by ELISA
in the vehicle group and each of the experimental groups. The
means and SDs are reported in Table 4 and indicate a widespread
physiological intra- and inter-monkey variability. sAPP and
sAPP concentrations were positively correlated (Pearson r 
0.98; **p 0.004; 95% CI: 0.706–0.999). However, A concen-
trations were not correlated to either sAPP (Pearson r 
0.063; p 0.92; 95% CI:0.895 to 0.868) or sAPP (Pearson
r  0.098; p  0.88; 95% CI: 0.902 to 0.859). With small
sample size, high precision is not expected, and this is evidenced
by the broad 95% CIs for the correlations involving A.
BACE inhibitor dose dependently decreased sAPP and A
in NHP CSF
Labeling curves of A (Fig. 4A) and sAPP (Fig. 4D), as well as
absolute concentrations of both analytes measured by ELISA
(Fig. 4B,E), decreased dose dependently in the presence of a
BACE inhibitor. Concentrations of newly generated metabolites
were calculated by taking the product of percentage labeled and
absolute concentration of a given metabolite at each time point.
Similarly to the labeling profiles and absolute concentrations, the
Figure 3. PK of MBI-5 indicate an increase of the BACE inhibitor incorporation into both plasma and CSF with increasing dose. A–C, Individual monkeys’ plasma concentrations of MBI-5 after
dosingwith 10, 30, and 125mg/kg.D–F, Individualmonkeys’ CSF concentrations ofMBI-5 after dosingwith 10, 30, or 125mg/kg.G, Individualmonkeys’ plasmaAUC59 at each dosage.H, Individual
monkeys’ CSF AUC59 at each dosage. I, Group-averaged plasma and CSF PK. Error bars indicate SD.
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newly generated A (Fig. 4C) and sAPP (Fig. 4F) reflect a dose-
dependent decrease in the presence of a BACE inhibitor. AUC
for A or sAPP labeling for each monkey after each dose of
BACE inhibitor were normalized to each monkey’s vehicle
labeling curve AUC and averaged. Dose-dependent decreases
were observed in AUC57 for A and sAPP when measured by
SILK, by ELISA, and in the newly generated peptide calcula-
tions (Table 5).
To determine the relative sensitivity of the assays in this study,
we calculatedMTSD values for SILKAUC57 versus ELISA AUC57
for each metabolite. MTSD was always higher for SILKmeasure-
ments when compared with ELISA, in all doses and for both
metabolites. In the cases of highest dose, SILK was clearly more
sensitive for sAPP (*p 0.05). The AMTSD was comparable
between the two methods used (p 0.22).
Mean values from each BACE inhibitor dosage group for each
analyte were compared with the mean value of each vehicle
group. The MFL A AUC57 (
13C6-A/
12C6-A) indicated a
dose-dependent decrease to48%of vehicle at the highest BACE
inhibitor dose of 125 mg/kg (Fig. 5A, Table 5);10% of the total
A is labeled. AUCs for ELISA concentrations of A normalized
to vehicle showed a dose-dependent response to33%of vehicle
(Fig. 5B, Table 5), a greater extent of reduction thanmeasured by
SILK. The newly synthesized A is only9% at the highest dos-
age of BACE inhibitor (Fig. 5C, Table 5). SILK MFL sAPP
AUC57 indicated a dose-dependent decrease to a lesser extent
than A: 70% of vehicle values at the highest BACE inhibitor
dose (Fig. 5D, Table 5), with 8% of the total sAPP being
labeled. AUCs for ELISA concentrations of sAPP normalized to
vehicle showed a dose-dependent response to 38% of vehicle
(Fig. 5E, Table 5), a greater extent of reduction thanmeasured by
SILK. Similarly toA, AUC57 values for newly synthesized sAPP
indicated a dose-dependent decrease to an even greater extent,
18% at the highest inhibitor dose, compared with SILK (Fig.
5F, Table 5). For graphical representation of AUC57 not normal-
ized to the vehicle, please refer to Figure 6.
BACE inhibition had no detectable effect on fraction labeled
sAPP but dose dependently increased total sAPP
concentrations measured by ELISA
The labeling curves of sAPP for vehicle and all three BACE
inhibitor groups indicated no significant differences in sAPP
fraction label (repeated-measures ANOVA, p  1.0; Fig. 4G).
SILKMFL sAPPAUC57 indicated a lack of significant difference
among dosage groups (Fig. 5G, Table 5). Concentrations mea-
sured by sAPP ELISA indicated a dose-dependent increase with
BACE inhibition (Fig. 4H). AUC 57 for absolute concentrations
of sAPP normalized to vehicle indicated a dose-dependent in-
crease to 131% at the highest dose (Fig. 5H, Table 5). Finally,
the newly generated sAPP (the product of steady-state concen-
tration multiplied by the fraction-labeled sAPP), demonstrated
dose-dependent increases (35%), but to a lesser degree than the
observed sAPP decrease (83%; Figs. 4I, 5I, Table 5). Again, to
determine the relative sensitivity of the assays in this study, we
calculatedMTSD values for SILKAUC57 versus ELISAAUC57 for
sAPP. MTSD was always higher for SILK measurements when
compared with ELISA in all doses (p  0.053). For graphical
representation of AUC57 not normalized to the vehicle, please
refer to Figure 6.
Discussion
To date, kinetic behavior of other APP fragments has not been
assessed in NHP, although Dobrowolska et al. (2008) demon-
strated total sAPP was metabolized 2-fold slower than A in
young, healthy humans. To our knowledge, although some basic
APP metabolism has been studied in pulse-chase experiments in
various cells lines (Weidemann et al., 1989;Oltersdorf et al., 1990;
Busciglio et al., 1993; Perez et al., 1996), there are no prior studies
investigating specific sAPP and sAPP metabolism in vivo.
Here, we present common features of sAPP and sAPPmetab-
olism measured in NHP CSF. Metabolism of these sAPP species,
relative to NHP A metabolism, was comparable to findings in
humans (Bateman et al., 2006; Dobrowolska et al., 2008) where
metabolic rates of both APP species were twice as slow as for A.
This correspondence between sAPP metabolism in both species
supports rhesus macaques as an appropriate preclinical model
Table 2. Individual monkey plasma PK parameters of MBI-5
Individual plasma PK parameters
at 10 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 4420 106,00 8370 15,700 12,400
Cmax (nM) 389.3 1487.6 698.8 1860.4 1136.0
Tmax (h) 5 3 3 5 3
Individual plasma PK parameters
at 30 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 36,300 40,900 35,600 70,100 58,200
Cmax (nM) 3274.2 3772.4 1792.6 5290.1 3113.8
Tmax (h) 5 5 16 7 5
Individual plasma PK parameters
at 125 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 205,000 272,000 247,000 628,000 408,000
Cmax (nM) 9744.8 13512.4 13430.3 24553.9 11961.8
Tmax (h) 9 13 16 13 31
Table 3. Individual monkey CSF PK parameters of MBI-5
Individual CSF PK parameters
at 10 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 211 541 540 686 663
Cmax (nM) 20.7 83.8 69.0 95.7 82.4
Tmax (h) 7 3 3 3 3
Individual CSF PK parameters
at 30 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 1820 2610 2110 3690 4030
Cmax (nM) 203.2 316.4 140.6 367.7 327.4
Tmax (h) 5 3 16 5 3
Individual CSF PK parameters
at 125 mg/kg MBI-5
Monkey # 1 2 3 4 5
AUC59 (nM*h) 2750 4910 3350 5270 4900
Cmax (nM) 180.8 356.6 265.3 273.4 171.2
Tmax (h) 13 5 13 16 3
Table 4. Individual monkeys’ baseline sAPP, sAPP, and A concentrations
pM (SD)
Mean baseline sAPP Mean baseline sAPP Mean baseline A
Monkey #
1 1306 (285) 1506 (214) 650 (287)
2 985 (175) 1058 (134) 863 (213)
3 877 (191) 1057 (127) 906 (284)
4 801 (194) 894 (127) 584 (163)
5 1224 (388) 1465 (346) 722 (286)
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surrogate for human CNS APP processing. The slower turnover
rates for these larger APP metabolites when compared with A
may be driven by delayed transport out of the brain.
In addition to the novel findings of A and sAPP kinetics
under steady-state conditions, this is the first report using
SILK to evaluate in vivo APP metabolite kinetics following
treatment with the BACE inhibitor MBI-5, which is distinct
from Merck’s BACE inhibitor MK-8931, currently in Phase 3
clinical trials. As expected, there was a notable, dose-
dependent decrease in A and sAPP in the presence of the
BACE inhibitor, indicating the drug hit its intended target.
The finding that there was a greater percentage reduction in
A compared with sAPP in the presence of the inhibitor was
consistent with A having faster kinetics at steady state (Fig.
2D,E, vehicle-treated group).
Because of conflicting results in previously reported studies
that have examined both sAPP and sAPP, it was unclear
whether the kinetics of -secretase processing of APP to sAPP
would also be altered in the presence of a BACE inhibitor. BACE
inhibitors applied in cell culture have sometimes led to apparent
shunting of APP down the -secretase pathway resulting in in-
creased sAPP secretion (Hussain et al., 2007; Fukumoto et al.,
2010), but not always (Kim et al., 2008). This has contrasted with
human studies that seemed to indicate a noncompetitive rela-
tionship between the -secretase and BACE APP processing
pathways (Gabelle et al., 2010; Lewczuk et al., 2010; Alexopolous
et al., 2012; Dobrowolska et al., 2014). Our reported baseline
positive correlation of sAPP and sAPP further supports this.
Nevertheless, pharmacological intervention may alter normal
Figure 4. Effects of a BACE inhibitor on SILK relative values, ELISA absolute concentrations, and concentrations of newly generated A (A–C), sAPP (D–F ), and sAPP (G–I ) in CSF of NHP. A,
D, G, SILK MFL A and sAPP decreases dose dependently with BACE inhibitor, andMFL sAPP indicated nomeasurable difference among vehicle and drug groups (measured by LC-MS). B, E,H,
Concentrations ofAand sAPPdecreaseddosedependently andabsolute concentrations of sAPP increaseddosedependentlywith aBACE inhibitor (measuredby ELISA).C,F, I, Newlygenerated
A and sAPP decreased dose dependently and newly generated sAPP increased dose dependently with a BACE inhibitor (measured as product of LC-MS labeling and ELISA absolute concen-
trations at each time point). Error bars indicate SD.









10 mg/kg 77.8 6.4% 111 12.9% 88.4 13.2%
30 mg/kg 70.8 7.0% 58.6 12.3% 37.8 11.5%
125 mg/kg 47.5 6.2% 33.2 8.2% 9.4 3.8%
sAPP (mean, SEM)
10 mg/kg 84.4 4.4% 88.1 2.1% 71.3 5.5%
30 mg/kg 78.3 3.4% 63.0 2.7% 42.1 3.9%
125 mg/kg 69.9 5.1% 38.3 4.4% 17.6 2.6%
sAPP (mean, SEM)
10 mg/kg 99.6 9.3% 107.8 7.4% 108.3 7.6%
30 mg/kg 101.0 3.2% 113.8 5.8% 123.1 7.4%
125 mg/kg 101.5 6.6% 131.4 6.9% 134.6 10.1%
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APP processing such that decreased BACE activity diverts APP
into the -secretase pathway, as demonstrated by May et al.
(2011) in humans after BACE1 inhibitor LY2811376 administra-
tion resulted in an increase of CSF sAPP corresponding to a
decrease of CSF sAPP. Our study in NHP suggests that different
APP fragment pools can manifest a spectrum of responses as
supported by these findings: (1) no apparent change in the MFL
sAPP during duration of BACE inhibition used in this study (as
well as a smaller degree of AUC changes in sAPP and A) and
(2) in contrast, the steady-state, absolute concentration of sAPP
demonstrated a dose-dependent sAPP concentration increase
(aswell as a larger degree of AUCchanges in sAPP andA). One
caveat to the ELISA measures is that sAPP did not increase to
the same extent that sAPP decreased (respective change from
vehicle at 125mg/kg in AUC57,35% and83%), and there was
no rebound of sAPP over baseline following the resumption of
BACE activity as drug levels declined. Thus, a build-up of APP
substrate may be degraded through mechanisms other than tra-
ditional-secretase cleavage activities to account for these obser-
vations. For example, recent IP studies indicate that alternative
- and -secretase processing may occur in vivo in human CNS,
i.e., sAPPQ686 (sAPP	), sAPPK687, sAPPM671, and sAPPY681
(sAPP	) from the APP770 splice variant (Brinkmalm et al.,
2013), which might not be detected with our SILK or ELISA
assays. Conversely, the additional APP substrate may undergo
lysosomal degradation. Measurements using SILK would not re-
flect APP shunted toward lysosomes, as these fragments would be
unlikely to travel to CSF.
The MFL profiles of A and sAPP were reduced in a dose-
dependentmannerwith increasing doses of BACE inhibitor, con-
comitant with decreased CSF concentrations of these proteins
measured by ELISA. In contrast, the MFL of sAPP was virtually
Figure 5. Effects of BACE inhibition on APPmetabolites’ AUC57. Results are represented as percentage change from vehicle AUC57. Each line represents a particular monkey. A,D,G, MFL A and
sAPP AUC57 were decreased dose dependently, while MFL sAPP AUC57 indicated that dosing groups did not significantly differ from the vehicle-treated group.B, E,H, AUC57 values for absolute
concentrations of A and sAPP were decreased dose dependently, while AUC57 of absolute concentrations of sAPP presented a dose-dependent increase. C, F, I, AUC57 values for newly
synthesized A and sAPPwere decreased dose dependently, while AUC57 of newly synthesized sAPP presented a dose-dependent increase.
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unaltered despite a dose-dependent increase of 30% in the
ELISA concentration AUC57 in the highest dose group (Fig.
5G,H, Table 5). This apparent dichotomy can be explained based
on simulations using nonsteady-state compartmental modeling
(B.W. Patterson, J. Stone, and E.M.T. van Maanen, unpublished
observations). BACE inhibitor was introduced around the same
time as 13C6-leucine tracer so the system transitioned from steady
state to a nonsteady state as tracer entered the system. We may
presume that the production of labeled A and sAPP was al-
most immediately decreased in a dose-dependent manner as
drug reached effective concentrations in the brain. The newly
synthesized, 13C6 leucine-labeled peptides moved into pools of
pre-existing CSF peptides that initially remained near basal abso-
lute concentrations, since turnover of the CSF pools must occur
before CSF concentrations decrease in response to BACE inhibi-
tion. The decreased appearance of labeled A and sAPP in CSF
preceded the decrease in CSF absolute concentration, comprised
of an excess of unlabeled peptides, thus resulting in a dose-
dependent decrease in the labeled to unlabeled peptide ratio (i.e.,
isotopic enrichment). BACE inhibition should, conversely, cause
the amount of APP substrate to increase, leading to increased
production of sAPP due to mass action. Thus, increasing
amounts of labeled sAPP should appear in CSF dose depend-
ently. The absolute concentration of CSF sAPP will increase
concomitant with, and in proportion to, increased appearance of
labeled sAPP, and thus there would be little impact to the la-
beled to unlabeled peptide ratio. In addition to the role of CSF
turnover on the differential sensitivity of both A and sAPP
enrichment profiles to acute inhibition versus an increase of
sAPP peptide synthesis, this also resulted in part because pep-
tides were sampled from a downstream location (CSF) remote
from the site of BACE activity (brain).
Figure 6. Effects of BACE inhibition on APP metabolites’ AUC57 without normalization to vehicle group. Each line represents a particular monkey. A, D, G, MFL A and sAPP AUC 57 were
decreased dose dependently, while MFL sAPP AUC57 indicated that dosing groups did not significantly differ from the vehicle-treated group. B, E, H, AUC57 values for absolute concentrations of
A and sAPP were decreased dose dependently, while AUC57 of absolute concentrations of three monkeys’ sAPP increased. Two monkeys did not show significant changes in sAPP.
Coincidentally, these twomonkeys had the lowest Cmax for the 125mg/kg dose among all themonkeys, andwere in the lower spectrum for Cmax at the 30mg/kg dose. C, F, I, AUC57 values for newly
synthesized A and sAPPwere decreased dose dependently, while AUC57 of newly synthesized of sAPP presented a dose-dependent increase.
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Further, of note is that in our study, for each metabolite, its
FSR is not equal to its FCR. The FSR and FCR are imperfect
indices of true turnover rate that are calculated under the as-
sumption of a single compartmental model. However, there are
many compartments in which APP may be processed and traf-
ficked in a complex mammalian organism setting. Thus, the FSR
calculations tend to be grossly underestimated and the true FSR is
likely much greater than what we report and probably quite sim-
ilar to our reported FCR, whose calculations are not perturbed by
the added complexity of additional compartments. The FSRs and
the FCRs reported here are useful in relative comparisons of the
three APP metabolites in this study, but a multicompartmental
model that fits the full time course could provide a closer estimate
of each metabolite’s true turnover rate. Such a modeling ap-
proach is currently under way.
A detailed mechanism-based, nonsteady-state PK–PD com-
partmentalmodel (Danhof et al., 2005) is also in progress andwill
account for both the ELISA concentration data and SILK tracer
enrichment time courses of APP metabolites as a function of
dynamic BACE inhibition for all doses of BACE inhibitor admin-
istered, versus vehicle treatment. Themodel will also incorporate
information from acute inhibition of -secretase activity (Cook
et al., 2010; Van Maanen et al., 2013).
The current study has the benefit of measuring changes in
APPmetabolites by two separatemethods: using SILK andMS, as
well as measuring absolute concentrations by ELISA. SILK is a
robust and reliable method of quantifying de novo proteins
changing over time following a labeling pulse, whereas the ELISA
assays measure the steady-state concentrations of a particular
metabolite. SILK ismore specific to newly generated proteins and
more sensitive to detect changes at earlier time points in a secre-
tase inhibitor setting (Bateman et al., 2009; Cook et al., 2010)
where protein ELISA variance may mask relatively smaller
changes in concentrations. Increased sensitivity of SILK is evi-
denced by the earlier appearance of the change in the ratio of label
versus the ELISA absolute concentration changes. Additionally,
SILK AUCs always had higher MTSD values than ELISA AUCs
among all dose groups and metabolites.
The CNS kinetic rates of APP metabolites are an important
physiologic measure that is tightly regulated and fairly consistent
across primates in studies to date. Modulation of APP processing
is a key approach in AD therapeutic development with BACE
inhibition being an attractive target. This is consistentwith recent
genetic evidence of a protective factor (Jonsson et al., 2012) in
individuals with amutation at the BACE cleavage site of APP that
prevents development of AD. The CNS in vivo study reported
here indicates that BACE inhibition modulated APP processing
in a predictable and dose-dependent fashion, but the study also
provides a novel finding into the balance of BACE and
-secretase APP processing following BACE inhibition.
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